首页> 外文期刊>Der Pharmacia Lettre >Concomitant delivery of Ofloxacin and Diclofenac sodium via pH triggeredin-situ ophthalmic gel: in-vitro and in-vivo consideration
【24h】

Concomitant delivery of Ofloxacin and Diclofenac sodium via pH triggeredin-situ ophthalmic gel: in-vitro and in-vivo consideration

机译:通过pH触发原位眼用凝胶剂同时给药氧氟沙星和双氯芬酸钠:体内和体外的考虑

获取原文
           

摘要

The aim of present study was to develop and evaluate in-situ ophthalmic gel system based on sol-to-gel transition for concomitant delivery of ofloxacin (OFL) and diclofenac sodium (DS) to facilitate sustained release to improveocular bioavailability and therapeutic response exhibited by conventional formulations.A 32 full factorial design was adopted to optimize the experimental conditions for development of formulation using Carbopol 940 and HPMC as independent variable. Developed formulations were characterized in terms of physical appearance, pH, viscosity, drug content, gelling capacity, and in-vitro drug release. Further, ex-vivo permeation and in-vivo irritation studies were conducted. The pH, viscosity and drug content of all developed formulations were found in the range of 5.2±0.02-6.5±0.04, 12±1.26-114±2.05cps and 88.32±2.26-98.46±1.36% respectively. The gel provided sustained drug release over an 8 h period. Furthermore, in-vivo ocular irritation study and antimicrobial efficiency of optimized formulation suggest that developed formulation was therapeutically efficacious and non-irritant. In conclusion, developed in-situ gelling system would be used to enhance ocular bioavailability of the loaded drugs and could reduce the frequency of instillation thereby improving patient compliance.
机译:本研究的目的是开发和评估基于溶胶-凝胶转变的原位眼用凝胶系统,用于氧氟沙星(OFL)和双氯芬酸钠(DS)的同时递送,以促进缓释,从而改善眼药水的生物利用度和治疗反应。采用Carbopol 940和HPMC作为自变量,采用32个全因子设计来优化开发配方的实验条件。根据物理外观,pH,粘度,药物含量,胶凝能力和体外药物释放来表征开发的制剂。此外,进行了体外渗透和体内刺激性研究。所有开发制剂的pH,粘度和药物含量分别为5.2±0.02-6.5±0.04、12±1.26-114±2.05cps和88.32±2.26-98.46±1.36%。凝胶在8小时内提供了持续的药物释放。此外,体内眼睛刺激性研究和优化配方的抗菌效果表明,开发的配方具有治疗效果且无刺激性。总之,开发的原位胶凝系统将用于增强药物的眼部生物利用度,并可以减少滴注的频率,从而改善患者的依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号